Generic placeholder image

The International Journal of Gastroenterology and Hepatology Diseases

Author(s): Anand Nath, Timothy R. Shope, Ivanesa L. Pardo Lameda and Timothy R. Koch*

DOI: 10.2174/0126662906296409240826050717

DownloadDownload PDF Flyer Cite As
Utility of the Non-Alcoholic Fatty Liver Disease Fibrosis Score in the Evaluation of Individuals with Medically-Complicated Obesity: A Retrospective Study

Article ID: e26662906296409 Pages: 6

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Individuals with high body mass index (BMI) are at risk for chronic liver disease. Liver biopsy is a gold standard for the diagnosis of liver disease, as well as for determining the NAFLD activity score and fibrosis stage. Blood alanine aminotransferase (ALT) can support the presence of steatohepatitis, while the non-alcoholic fatty liver disease (NAFLD) fibrosis score (using clinical features and blood testing) may predict fibrosis. Based on prior studies, it is not clear whether the NAFLD fibrosis score is predictive of the NAFLD activity score or fibrosis stage.

Aims: The aim was to examine whether clinical features and blood testing can identify the risk of chronic liver disease in those individuals with high BMI.

Objective: Individuals with high BMI who may benefit from bariatric surgery were examined for the prevalence of steatohepatitis and for potential relationships between the NAFLD fibrosis score and the NAFLD activity score and fibrosis stage.

Methods: This was a retrospective study of 593 consecutive individuals evaluated for bariatric surgery who underwent blood testing. Seventy individuals with a mean BMI of 49.9 kg/m2 underwent liver biopsy at surgery.

Results: Elevated ALT was present in 102 subjects (17.2%). The correlation coefficient (R: 0.025; p = 0.83) between the NAFLD fibrosis score and NAFLD activity score was not significant, but there was a weak correlation between the NAFLD fibrosis score and fibrosis stage (R = 0.262; p = 0.28). Two individuals (3%) had cirrhosis.

Conclusion: Elevated ALT may support the presence of liver disease in individuals with high BMI. There is a weak correlation between the NAFLD fibrosis score and the fibrosis stage. Further work is required to determine whether specific blood and clinical findings can be useful in making clinical decisions with regards to bariatric surgery in those individuals with high BMI.

Keywords: Non-alcoholic fatty liver disease, steatohepatitis, biopsy, alanine aminotransferase, body mass index, body size.

[1]
Boutari, C.; Mantzoros, C.S. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism, 2022, 133, 155217.
[http://dx.doi.org/10.1016/j.metabol.2022.155217] [PMID: 35584732]
[2]
Jensen, M.D.; Ryan, D.H.; Apovian, C.M.; Ard, J.D.; Comuzzie, A.G.; Donato, K.A.; Hu, F.B.; Hubbard, V.S.; Jakicic, J.M.; Kushner, R.F.; Loria, C.M.; Millen, B.E.; Nonas, C.A.; Pi-Sunyer, F.X.; Stevens, J.; Stevens, V.J.; Wadden, T.A.; Wolfe, B.M.; Yanovski, S.Z.; Jordan, H.S.; Kendall, K.A.; Lux, L.J.; Mentor-Marcel, R.; Morgan, L.C.; Trisolini, M.G.; Wnek, J.; Anderson, J.L.; Halperin, J.L.; Albert, N.M.; Bozkurt, B.; Brindis, R.G.; Curtis, L.H.; DeMets, D.; Hochman, J.S.; Kovacs, R.J.; Ohman, E.M.; Pressler, S.J.; Sellke, F.W.; Shen, W-K.; Smith, S.C., Jr; Tomaselli, G.F. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation, 2014, 129(25_suppl_2), S102-S138.
[http://dx.doi.org/10.1161/01.cir.0000437739.71477.ee] [PMID: 24222017]
[3]
Shah, R.A.; Nath, A.; Shope, T.R.; Pardo Lameda, I.L.; Brebbia, J.S.; Koch, T.R. Obesity subtypes and short term weight loss after vertical sleeve gastrectomy: A retrospective cohort study. J. Gastroent. Hep. Res., 2022, 11(5), 3759-3764.
[http://dx.doi.org/10.17554/j.issn.2224-3992.2022.11.1061]
[4]
Riazi, K.; Azhari, H.; Charette, J.H.; Underwood, F.E.; King, J.A.; Afshar, E.E.; Swain, M.G.; Congly, S.E.; Kaplan, G.G.; Shaheen, A.A. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 2022, 7(9), 851-861.
[http://dx.doi.org/10.1016/S2468-1253(22)00165-0] [PMID: 35798021]
[5]
Hsueh, W.; Shope, T.R.; Koch, T.R.; Smith, C.I. Bariatric surgery for the treatment of nonalcoholic fatty liver disease: Is vertical sleeve gastrectomy the best future option? J. Gastroenterol. Hepatol. Res., 2016, 5(2), 1957-1961.
[http://dx.doi.org/10.17554/j.issn.2224-3992.2016.05.564]
[6]
Kleiner, D.E.; Brunt, E.M.; Van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.C.; Torbenson, M.S.; Unalp-Arida, A.; Yeh, M.; McCullough, A.J.; Sanyal, A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41(6), 1313-1321.
[http://dx.doi.org/10.1002/hep.20701] [PMID: 15915461]
[7]
Brunt, E.M.; Kleiner, D.E.; Wilson, L.A.; Belt, P.; Neuschwander-Tetri, B.A. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology, 2011, 53(3), 810-820.
[http://dx.doi.org/10.1002/hep.24127] [PMID: 21319198]
[8]
Angulo, P.; Hui, J.M.; Marchesini, G.; Bugianesi, E.; George, J.; Farrell, G.C.; Enders, F.; Saksena, S.; Burt, A.D.; Bida, J.P.; Lindor, K.; Sanderson, S.O.; Lenzi, M.; Adams, L.A.; Kench, J.; Therneau, T.M.; Day, C.P. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45(4), 846-854.
[http://dx.doi.org/10.1002/hep.21496] [PMID: 17393509]
[9]
Udelsman, B.V.; Corey, K.; Hutter, M.M.; Chang, D.C.; Witkowski, E.R. Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. Surg. Obes. Relat. Dis., 2021, 17(2), 292-298.
[http://dx.doi.org/10.1016/j.soard.2020.09.037] [PMID: 33153965]
[10]
Simo, K.A.; McKillop, I.H.; McMillan, M.T.; Ahrens, W.A.; Walters, A.L.; Thompson, K.J.; Kuwada, T.S.; Martinie, J.B.; Iannitti, D.A.; Gersin, K.S.; Sindram, D. Does a calculated “NAFLD fibrosis score” reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes. Surg., 2014, 24(1), 15-21.
[http://dx.doi.org/10.1007/s11695-013-1044-6] [PMID: 23934335]
[11]
Schmitz, S.M.T.; Kroh, A.; Ulmer, T.F.; Andruszkow, J.; Luedde, T.; Brozat, J.F.; Neumann, U.P.; Alizai, P.H. Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems. BMC Gastroenterol., 2020, 20(1), 254.
[http://dx.doi.org/10.1186/s12876-020-01400-1] [PMID: 32758151]
[12]
Singh, S.; Venkatesh, S.K.; Wang, Z.; Miller, F.H.; Motosugi, U.; Low, R.N.; Hassanein, T.; Asbach, P.; Godfrey, E.M.; Yin, M.; Chen, J.; Keaveny, A.P.; Bridges, M.; Bohte, A.; Murad, M.H.; Lomas, D.J.; Talwalkar, J.A.; Ehman, R.L. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin. Gastroenterol. Hepatol., 2015, 13(3), 440-451.e6.
[http://dx.doi.org/10.1016/j.cgh.2014.09.046] [PMID: 25305349]
[13]
Ziol, M.; Handra-Luca, A.; Kettaneh, A.; Christidis, C.; Mal, F.; Kazemi, F.; de Lédinghen, V.; Marcellin, P.; Dhumeaux, D.; Trinchet, J.C.; Beaugrand, M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology, 2005, 41(1), 48-54.
[http://dx.doi.org/10.1002/hep.20506] [PMID: 15690481]
[14]
Myers, R.P.; de Torres, M.; Imbert-Bismut, F.; Ratziu, V.; Charlotte, F.; Poynard, T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig. Dis. Sci., 2003, 48(1), 146-153.
[http://dx.doi.org/10.1023/A:1021702902681] [PMID: 12645802]
[15]
Naveau, S.; Gaudé, G.; Asnacios, A.; Agostini, H.; Abella, A.; Barri-Ova, N.; Dauvois, B.; Prévot, S.; Ngo, Y.; Munteanu, M.; Balian, A.; Njiké-Nakseu, M.; Perlemuter, G.; Poynard, T. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology, 2009, 49(1), 97-105.
[http://dx.doi.org/10.1002/hep.22576] [PMID: 19053048]
[16]
Ooi, G.J.; Mgaieth, S.; Eslick, G.D.; Burton, P.R.; Kemp, W.W.; Roberts, S.K.; Brown, W.A. Systematic review and meta‐analysis: non‐invasive detection of non‐alcoholic fatty liver disease related fibrosis in the obese. Obes. Rev., 2018, 19(2), 281-294.
[http://dx.doi.org/10.1111/obr.12628] [PMID: 29119725]
[17]
Smith, J.O.; Sterling, R.K. Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C. Aliment. Pharmacol. Ther., 2009, 30(6), 557-576.
[http://dx.doi.org/10.1111/j.1365-2036.2009.04062.x] [PMID: 19519733]
[18]
Kwo, P.Y.; Cohen, S.M.; Lim, J.K. ACG clinical guideline: evaluation of abnormal liver chemistries. Am. J. Gastroenterol., 2017, 112(1), 18-35.
[http://dx.doi.org/10.1038/ajg.2016.517] [PMID: 27995906]
[19]
Verhaegh, P.; Bavalia, R.; Winkens, B.; Masclee, A.; Jonkers, D.; Koek, G. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2018, 16(6), 837-861.
[http://dx.doi.org/10.1016/j.cgh.2017.08.024] [PMID: 28838784]
[20]
Seki, Y.; Kakizaki, S.; Horiguchi, N.; Hashizume, H.; Tojima, H.; Yamazaki, Y.; Sato, K.; Kusano, M.; Yamada, M.; Kasama, K. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. J. Gastroenterol., 2016, 51(3), 281-289.
[http://dx.doi.org/10.1007/s00535-015-1114-8] [PMID: 26314837]
[21]
Meneses, D.; Olveira, A.; Corripio, R.; Méndez, M.C.; Romero, M.; Calvo-Viñuelas, I.; Herranz, L.; Vicent, D.; de-Cos-Blanco, A.I. Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. Endocrinología, Diabetes y Nutrición (English ed.), 2022, 69(3), 178-188.
[http://dx.doi.org/10.1016/j.endien.2022.02.017] [PMID: 35396116]
[22]
Lembo, E.; Russo, M.F.; Verrastro, O.; Anello, D.; Angelini, G.; Iaconelli, A.; Guidone, C.; Stefanizzi, G.; Ciccoritti, L.; Greco, F.; Sessa, L.; Riccardi, L.; Pompili, M.; Raffaelli, M.; Vecchio, F.M.; Bornstein, S.R.; Mingrone, G.; Gastaldelli, A.; Capristo, E. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. Diabetes Metab., 2022, 48(5), 101363.
[http://dx.doi.org/10.1016/j.diabet.2022.101363] [PMID: 35760372]
[23]
Pan, J.J.; Fallon, M.B. Gender and racial differences in nonalcoholic fatty liver disease. World J. Hepatol., 2014, 6(5), 274-283.
[http://dx.doi.org/10.4254/wjh.v6.i5.274] [PMID: 24868321]
[24]
Bonacini, M.; Kassamali, F.; Kari, S.; Lopez Barrera, N.; Kohla, M. Racial differences in prevalence and severity of non-alcoholic fatty liver disease. World J. Hepatol., 2021, 13(7), 763-773.
[http://dx.doi.org/10.4254/wjh.v13.i7.763] [PMID: 34367497]
[25]
Ruhl, C.E.; Everhart, J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology, 2003, 124(1), 71-79.
[http://dx.doi.org/10.1053/gast.2003.50004] [PMID: 12512031]
[26]
Satapathy, S.K.; Marella, H.K.; Heda, R.P.; Ganguli, S.; Kirthi Reddy, Y.; Podila, P.S.B.; Clark, I.; Maliakkal, B. African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians. Eur. J. Gastroenterol. Hepatol., 2021, 33(3), 388-398.
[http://dx.doi.org/10.1097/MEG.0000000000001735] [PMID: 32317586]
[27]
Younossi, Z.M.; Noureddin, M.; Bernstein, D.; Kwo, P.; Russo, M.; Shiffman, M.L.; Younes, Z.; Abdelmalek, M. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: Expert panel recommendations. Am. J. Gastroenterol., 2021, 116(2), 254-262.
[http://dx.doi.org/10.14309/ajg.0000000000001054] [PMID: 33284184]
[28]
Kabbany, M.N.; Selvakumar, P.K.C.; Watt, K.; Lopez, R.; Akras, Z.; Zein, N.; Carey, W.; Alkhouri, N. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data. Am. J. Gastroenterol., 2017, 112(4), 581-587.
[http://dx.doi.org/10.1038/ajg.2017.5] [PMID: 28195177]
[29]
Taylor, R.S.; Taylor, R.J.; Bayliss, S.; Hagström, H.; Nasr, P.; Schattenberg, J.M.; Ishigami, M.; Toyoda, H.; Wai-Sun Wong, V.; Peleg, N.; Shlomai, A.; Sebastiani, G.; Seko, Y.; Bhala, N.; Younossi, Z.M.; Anstee, Q.M.; McPherson, S.; Newsome, P.N. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology, 2020, 158(6), 1611-1625.e12.
[http://dx.doi.org/10.1053/j.gastro.2020.01.043] [PMID: 32027911]
[30]
Eilenberg, M.; Munda, P.; Stift, J.; Langer, F.B.; Prager, G.; Trauner, M.; Staufer, K. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg. Nutr., 2021, 10(5), 610-622.
[http://dx.doi.org/10.21037/hbsn-20-787] [PMID: 34760965]
[31]
Lee, Y.; Doumouras, A.G.; Yu, J.; Brar, K.; Banfield, L.; Gmora, S.; Anvari, M.; Hong, D. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2019, 17(6), 1040-1060.e11.
[http://dx.doi.org/10.1016/j.cgh.2018.10.017] [PMID: 30326299]
[32]
Adams, T.D.; Meeks, H.; Fraser, A.; Davidson, L.E.; Holmen, J.; Newman, M.; Ibele, A.R.; Richards, N.; Hunt, S.C.; Kim, J. LONG‐TERM ALL‐CAUSE and CAUSE‐SPECIFIC mortality for four bariatric surgery procedures. Obesity (Silver Spring), 2023, 31(2), 574-585.
[http://dx.doi.org/10.1002/oby.23646] [PMID: 36695060]
[33]
Krishnan, A.; Hadi, Y.; Alqahtani, S.A.; Woreta, T.A.; Fang, W.; Abunnaja, S.; Szoka, N.; Tabone, L.E.; Thakkar, S.; Singh, S. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw. Open, 2023, 6(4), e237188.
[http://dx.doi.org/10.1001/jamanetworkopen.2023.7188] [PMID: 37027156]
[34]
Edholm, D.; Kullberg, J.; Haenni, A.; Anders Karlsson, F.; Ahlström, A.; Hedberg, J.; Ahlström, H.; Sundbom, M. Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese. Obes. Surg., 2011, 21(3), 345-350.
[http://dx.doi.org/10.1007/s11695-010-0337-2] [PMID: 21181291]